AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Angelini Ventures has already invested €125 million in 22 startups
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Subscribe To Our Newsletter & Stay Updated